Routine use of PET scans after completion of therapy in pediatric Hodgkin disease results in a high false positive rate

Journal of Pediatric Hematology/Oncology

Volumn 28, Issue 11, 2006, Pages 711-714

  Levine, Jennifer M ^a,b   Weiner, Michael ^a   Kelly, Kara M ^a  

^a College of Physicians and Surgeons ^*  (United States)

^b IP 7 ^*  (United States)

Author keywords

Disease surveillance; Hodgkin disease; Positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ABDOMINAL WALL HERNIA; ADOLESCENT; ADULT; APPENDICITIS; ARTICLE; CANCER GROWTH; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE COURSE; FEMALE; FIBROSIS; HODGKIN DISEASE; HUMAN; LABORATORY DIAGNOSIS; LYMPHADENOPATHY; MALE; MEDICAL RECORD REVIEW; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; FALSE POSITIVE REACTIONS; FEMALE; FLUORODEOXYGLUCOSE F18; HODGKIN DISEASE; HUMANS; MALE; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES;

EID: 33751245120     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/01.mph.0000243648.66734.eb     Document Type: Article

References (28)

1. Sasaki M, Kuwabara Y, Koga H, et al. Clinical impact of whole body FDG-PET on the staging and therapeutic decision making for malignant lymphoma. Ann Nucl Med. 2002;16:337-345.
2. Wirth A, Seymour JF, Hicks RJ, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma. Am J Med. 2002;112:262-268.
3. Friedberg JW, Fischman A, Neuberg D, et al. FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma: a blinded comparison. Leuk Lymphoma. 2004;45:85-92.
4. Hueltenschmidt B, Sautter-Bihl ML, Lang O, et al. Whole body positron emission tomography in the treatment of Hodgkin disease. Cancer. 2001;91:302-310.
5. Munker R, Glass J, Griffeth LK, et al. Contribution of PET imaging to the initial staging and prognosis of patients with Hodgkin's disease. Ann Oncol. 2004;15:1699-1704.
6. Jerusalem G, Hustinx R, Beguin Y, et al. Positron emission tomography imaging for lymphoma. Curr Opin Oncol. 2005;17:441-445.
7. Hutchings M, Mikhaeel NG, Fields PA, et al. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol. 2005;16:1160-1168.
8. Kostakoglu L, Coleman M, Leonard JP, et al. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med. 2002;43:1018-1027.
9. Depas G, De Barsy C, Jerusalem G, et al. 18F-FDG PET in children with lymphomas. Eur J Nucl Med Mol Imaging. 2005;32:31-38.
10. Hernandez-Pampaloni M, Takalkar A, Yu JQ, et al. F-18 FDG-PET imaging and correlation with CT in staging and follow-up of pediatric lymphomas. Pediatr Radiol. 2006;36:524-531.
11. Kabickova E, Sumerauer D, Cumlivska E, et al. Comparison of (18)F-FDG-PET and standard procedures for the pretreatment staging of children and adolescents with Hodgkin's disease. Eur J Nucl Med Mol Imaging. 2006;33:1025-1031.
12. Guay C, Lepine M, Verreault J, et al. Prognostic value of PET using 18F-FDG in Hodgkin's disease for posttreatment evaluation. J Nucl Med. 2003;44:1225-1231.
13. Jerusalem G, Beguin Y, Fassotte MF, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood. 1999;94:429-433.
14. Naumann R, Vaic A, Beuthien-Baumann B, et al. Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Br J Haematol. 2001;115:793-800.
15. Weihrauch MR, Re D, Scheidhauer K, et al. Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood. 2001;98:2930-2934.
16. Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology. 2004;231:305-332.
17. Panizo C, Perez-Salazar M, Bendandi M, et al. Positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual Hodgkin's disease mediastinal masses. Leuk Lymphoma. 2004;45:1829-1833.
18. Maisey NR, Hill ME, Webb A, et al. Are 18fluorodeoxyglucose positron emission tomography and magnetic resonance imaging useful in the prediction of relapse in lymphoma residual masses? Eur J Cancer. 2000;36:200-206.
19. Jerusalem G, Beguin Y, Fassotte MF, et al. Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease. Ann Oncol. 2003;14:123-130.
20. Yeung HW, Grewal RK, Gonen M, et al. Patterns of (18)F-FDG uptake in adipose tissue and muscle: a potential source of false-positives for PET. J Nucl Med. 2003;44:1789-1796.
21. Sandherr M, von Schilling C, Link T, et al. Pitfalls in imaging Hodgkin's disease with computed tomography and positron emission tomography using fluorine-18-fluorodeoxyglucose. Ann Oncol. 2001;12:719-722.
22. Kaste SC, Howard SC, McCarville EB, et al. 18F-FDG-avid sites mimicking active disease in pediatric Hodgkin's. Pediatr Radiol. 2005;35:141-154.
23. Smith RS, Chen Q, Hudson MM, et al. Prognostic factors for children with Hodgkin's disease treated with combined-modality therapy. J Clin Oncol. 2003;21:2026-2033.
24. Rhodes MM, Delbeke D, Whitlock JA, et al. Utility of FDG-PET/CT in follow-up of children treated for Hodgkin and non-Hodgkin lymphoma. J Pediatr Hematol Oncol. 2006;28:300-306.
25. Meany HGV, Minniti C. Utility of PET scan to predict relaspe in pediatric patients with Hodgkin's disease [abstract 1131]. Pediatr Blood Cancer. 2005;44:556.
26. Montravers F, McNamara D, Landman-Parker J, et al. [(18)F]FDG in childhood lymphoma: clinical utility and impact on management. Eur J Nucl Med Mol Imaging. 2002;29:1155-1165.
27. Cook GJ, Maisey MN, Fogelman I. Normal variants, artefacts and interpretative pitfalls in PET imaging with 18-fluoro-2-deoxyglucose and carbon-11 methionine. Eur J Nucl Med. 1999;26:1363-1378.
28. Radford JA, Eardley A, Woodman C, et al. Follow up policy after treatment for Hodgkin's disease: too many clinic visits and routine tests? A review of hospital records. BMJ. 1997;314:343-346.